+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Small-Molecule Antiviral β-d- N 4 -Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance



Small-Molecule Antiviral β-d- N 4 -Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance



Journal of Virology 93(24)



Coronaviruses (CoVs) have emerged from animal reservoirs to cause severe and lethal disease in humans, but there are currently no FDA-approved antivirals to treat the infections. One class of antiviral compounds, nucleoside analogues, mimics naturally occurring nucleosides to inhibit viral replication. While these compounds have been successful therapeutics for several viral infections, mutagenic nucleoside analogues, such as ribavirin and 5-fluorouracil, have been ineffective at inhibiting CoVs. This has been attributed to the proofreading activity of the viral 3'-5' exoribonuclease (ExoN). β-d-N 4-Hydroxycytidine (NHC) (EIDD-1931; Emory Institute for Drug Development) has recently been reported to inhibit multiple viruses. Here, we demonstrate that NHC inhibits both murine hepatitis virus (MHV) (50% effective concentration [EC50] = 0.17 μM) and Middle East respiratory syndrome CoV (MERS-CoV) (EC50 = 0.56 μM) with minimal cytotoxicity. NHC inhibited MHV lacking ExoN proofreading activity similarly to wild-type (WT) MHV, suggesting an ability to evade or overcome ExoN activity. NHC inhibited MHV only when added early during infection, decreased viral specific infectivity, and increased the number and proportion of G:A and C:U transition mutations present after a single infection. Low-level NHC resistance was difficult to achieve and was associated with multiple transition mutations across the genome in both MHV and MERS-CoV. These results point to a virus-mutagenic mechanism of NHC inhibition in CoVs and indicate a high genetic barrier to NHC resistance. Together, the data support further development of NHC for treatment of CoVs and suggest a novel mechanism of NHC interaction with the CoV replication complex that may shed light on critical aspects of replication.IMPORTANCE The emergence of coronaviruses (CoVs) into human populations from animal reservoirs has demonstrated their epidemic capability, pandemic potential, and ability to cause severe disease. However, no antivirals have been approved to treat these infections. Here, we demonstrate the potent antiviral activity of a broad-spectrum ribonucleoside analogue, β-d-N 4-hydroxycytidine (NHC), against two divergent CoVs. Viral proofreading activity does not markedly impact sensitivity to NHC inhibition, suggesting a novel interaction between a nucleoside analogue inhibitor and the CoV replicase. Further, passage in the presence of NHC generates only low-level resistance, likely due to the accumulation of multiple potentially deleterious transition mutations. Together, these data support a mutagenic mechanism of inhibition by NHC and further support the development of NHC for treatment of CoV infections.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 069388876

Download citation: RISBibTeXText

PMID: 31578288


Related references

Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay. Journal of Virology 88(8): 4353-4365, 2014

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. Mbio 9(2):, 2018

Novel Protease Inhibitors Containing C-5-Modified bis -Tetrahydrofuranylurethane and Aminobenzothiazole as P2 and P2' Ligands That Exert Potent Antiviral Activity against Highly Multidrug-Resistant HIV-1 with a High Genetic Barrier against the Emergence of Drug Resistance. Antimicrobial Agents and ChemoTherapy 63(8):, 2019

Effect of proofreading and dam-instructed mismatch repair systems on N4-hydroxycytidine-induced mutagenesis. Molecular and General Genetics 186(3): 411-418, 1982

Effect of proofreading anddam-instructed mismatch repair systems on N4-hydroxycytidine-induced mutagenesis. Molecular Genetics and Genomics 186(3): 411-418, 1982

The ADP-ribose-1''-monophosphatase domains of severe acute respiratory syndrome coronavirus and human coronavirus 229E mediate resistance to antiviral interferon responses. Journal of General Virology 92(Pt 8): 1899-1905, 2011

Synthesis, antiviral activity and resistance of a novel small molecule HIV-1 entry inhibitor. Bioorganic and Medicinal Chemistry 23(24): 7618-7628, 2015

Influenza Virus: Small Molecule Therapeutics and Mechanisms of Antiviral Resistance. Current Medicinal Chemistry 25(38): 5115-5127, 2018

The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance. Current Opinion in Virology 2(5): 644-650, 2012

Pharmacological Characterization of the Spectrum of Antiviral Activity and Genetic Barrier to Drug Resistance of M2-S31N Channel Blockers. Molecular Pharmacology 90(3): 188-198, 2016

Inhibition of Severe Acute Respiratory Syndrome-Associated Coronavirus (SarscoV) by Calpain Inhibitors and -D-N4-Hydroxycytidine. Antiviral Chemistry and Chemotherapy 15(1): 15-22, 2004

New N4-Hydroxycytidine Derivatives: Synthesis and Antiviral Activity. Collection of Czechoslovak Chemical Communications 71(7): 1099-1106, 2006

Gs-5816, A Second Generation Hcv Ns5A Inhibitor With Potent Antiviral Activity, Broad Genotypic Coverage And A High Resistance Barrier. Journal of Hepatology 58: S484-S485, 2013

Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-D-N4-hydroxycytidine. Antiviral Chemistry & ChemoTherapy 15(1): 15-22, 2004

High throughput screening for small molecule enhancers of the interferon signaling pathway to drive next-generation antiviral drug discovery. Plos one 7(5): E36594, 2012